RETATRUTIDE

Retatrutide (research code LY3437943) is a cutting-edge research peptide and a novel next-generation triple agonist. It is the first molecule of its class to highly selectively and simultaneously bind to three crucial metabolic receptors: the GIP receptor (glucose-dependent insulinotropic polypeptide), the GLP-1 receptor (glucagon-like peptide-1), and the Glucagon receptor (GCG-R).

This unique triple mechanism of action sets Retatrutide fundamentally apart from previous dual agonists like Tirzepatide or mono-agonists like Semaglutide. While GIP and GLP-1 primarily modulate insulin secretion and control satiety via the central nervous system, the additional activation of the glucagon receptor opens up an entirely new metabolic pathway. This pathway directly targets the increase of basal energy expenditure and promotes hepatic lipid oxidation (fat burning in the liver). This synergistic effect makes Retatrutide one of the most promising and intensely studied peptides in global metabolic research.

Groundbreaking Study Results: The Scientific Foundation

The scientific and clinical relevance of Retatrutide is supported, among other data, by the highly acclaimed Phase 2 study by Jastreboff et al., published in 2023 in the prestigious New England Journal of Medicine (NEJM) (PubMed ID: 37385275). In this randomized, double-blind, and placebo-controlled trial, the peptide demonstrated unprecedented results over a 48-week period:

• Significant Weight Reduction: In the highest dosage group evaluated, a dose-dependent reduction in body weight of up to 24.2% was achieved—a figure that significantly surpasses previously published results for comparable substances in obesity and metabolic research.
• Improvement of Cardiometabolic Parameters: Alongside massive weight loss, significant improvements were observed in essential biomarkers, including optimized HbA1c levels, lowered fasting glucose, and a marked enhancement of the lipid profile.
• Liver Health: Particularly noteworthy were the positive effects on the reduction of liver fat, making Retatrutide a highly interesting candidate for research models focusing on NAFLD (non-alcoholic fatty liver disease) and NASH.

Biochemical Properties and Stability

At Bergdorf Bioscience, Retatrutide is supplied as a high-purity, lyophilized (freeze-dried) powder. This complex manufacturing process extracts moisture from the peptide, ensuring maximum chemical stability and an exceptionally long shelf life, even at room temperature.